ProHance has shown itself to be extremely safe in clinical use. Only a small percentage of side effects have been demonstrated in clinical tests (21,25,26)
Its safety profile has also been confirmed in clinical trials using high doses (0.3 mmol/kg) (23,28*)

ProHance has the lowest osmolality of compared contrast media for magnetic resonance examinations (9). Thanks to its low osmolality, ProHance (gadoteridol 0.1 mmol/kg) does not appear to produce changes in haemodynamic parameters (10*)

ProHance has the lowest viscosity of compared contrast media for magnetic resonance examinations. The low viscosity of ProHance allows rapid injections and enables the use of thinner injection needles, making the procedure less uncomfortable for the patient.

ProHance has been shown to produce excellent contrast enhancement in magnetic resonance examinations of the brain and spinal column. ProHance provides increased information compared with examination results from before the injection of the contrast medium. (21,22,23*)

ProHance has proved to be especially valuable for improving the visualisation of pathological brain and spinal column changes, as well as for defining the scope and classification of the pathology. (26*)

The increased information obtained with the use of ProHance has an important impact on the diagnosis. Thanks to the increased information obtained, the therapy for patients with previously suspected CNS pathology may be changed. (24*)

If an extra injection of ProHance is considered necessary, an extra dose of 0.1 mmol/kg can be administered 30 minutes after the first. This provides a total dose of 0.2 mmol/kg.

In preclinical trials, ProHance has shown very low acute toxicity (18*)
ProHance has displayed high tolerability after repeated administration (18*)
ProHance displays no potential for haemolysis in human cells (18*)
No effect on iron levels has been observed in the blood of laboratory animals even at high doses of ProHance (18*)

* See attached brochure